Humans and rodents exhibit a peculiar type of placentation in which zygote-derived trophoblast cells, rather than endothelial cells, line the terminal maternal vascular space. This peculiar aspect of the placental vasculature raises important questions about the relative contribution of fetal and maternal factors in the local control of hemostasis in the placenta, and how these might determine the phenotypic expression of thrombophilia-associated complications of pregnancy. Using genome-wide expression analysis, we identify a panel of genes that determine the ability of fetal trophoblast cells to regulate hemostasis at the feto-maternal interface. We show that spontaneous differentiation of trophoblast stem cells is associated with the acquisition of an endothelial cell-like thromboregulatory gene expression program. This program is developmentally regulated and conserved between mice and humans. We further show that trophoblast cells sense, via the expression of protease activated receptors, the presence of activated coagulation factors.
thrombomodulin (TM), endothelial protein C receptor (EPCR) and tissue factor pathway inhibitor (TFPI) [4] [5] [6] [7] [8] . Such findings indicate that trophoblast cells might exhibit an endothelial cell-like ability to partake in the regulation of hemostasis at the feto-maternal interface. Indeed, the term "endothelial mimicry" has been coined to describe a process of remodeling of the maternal arteries, during which so-called "endovascular" trophoblast cells replace the maternal endothelium in these blood vessels, and switch their expression from epithelial to endothelial adhesion receptor repertoire [9] [10] [11] . It is unknown whether trophoblast cells acquire anticoagulant gene expression in a temporally and spatially controlled manner similar to that described for the subset of endovascular trophoblast cells; or whether the acquisition of an endothelial cell-like anticoagulant phenotype is a cell type-defining feature of trophoblast cells in general.
The placenta is also a rich source of the initiator of coagulation, tissue factor (TF). TF antigen and procoagulant activity are detected in mouse giant and labrynthine trophoblasts and on human syncytiotrophoblast membranes [12] [13] [14] [15] . With the exception of angiogenic endothelium, and in endothelium subjected to inflammatory and thrombotic stimuli, TF expression is strictly excluded from endothelial cells. Proinflammatory cytokines, ligands for Toll-receptors, and the principal coagulation protease, thrombin, induce TF expression in cultured endothelial cells, evoke increased production of endothelial-leukocyte adhesion receptors, and simultaneously suppress the expression of anti-coagulant gene products. This transition from a non-coagulant and antiadhesive phenotype to a state of enhanced coagulation and leukocyte interactions has been termed "endothelial activation", and appears to reflect a principal switch in a concerted gene expression program 16 . In contrast, trophoblast cells constitutively express TF, thus exhibiting, even under normal conditions, a hallmark of activated endothelium. At least in mice, constitutive expression of tissue factor by placental trophoblast cells is essential for normal placental function 14 .
Constitutive TF expression at the blood-tissue interface sets the vascular bed of the placenta aside from the circulatory system of other organs. This pro-coagulant feature of trophoblast cells could, unless tightly controlled by anticoagulant mechanisms, predispose the placental vascular bed to organ-specific thrombosis. Indeed inherited and acquired thrombophilia of the mother, such as that caused by factor V (fV) and prothrombin gene mutations, correlate
with an increased incidence of fetal loss at various stages of gestation, and with other obstetric complications, such as pre-eclampsia, intrauterine growth restriction (IUGR), placental abruption, and stillbirth [17] [18] [19] [20] [21] . Yet, the strength of the association between maternal thrombophilia and adverse pregnancy outcome is highly variable between studies, indicating the existence of as yet uncharacterized risk modifiers. In theory, prothrombotic alterations in fetal trophoblast function could dramatically affect the local haemostatic balance in the placenta, since this would be precisely the locale where such risk factors would compound the systemic thrombophilia of the mother.
Tissue factor activity produced by trophoblast cells may also affect the interplay between coagulation activation and cellular signaling processes mediated by receptors for activated coagulation factors. Contact of TF-bearing trophoblast cells with blood-borne fVII and fX would yield signaling-competent TF-VIIa and TF-VIIa-Xa complexes that can activate protease activated receptor (PAR) 1 and PAR 2 directly, or indirectly, via the TF-initiated production of the coagulation proteases thrombin and fXa. Such ligand-receptor interactions may couple coagulation activation to trophoblast physiology, and thereby affect the development and function of the placenta. For example, thrombin inhibits the proliferation, and regulates the invasiveness of trophoblast cells, and these effects are mediated at least in part through the engagement of 
Material and Methods: Cell Culture
During placental organogenesis a small population of self-renewing and lineagerestricted fetal precursor cells (trophoblast stem cells; TS cells) give rise to these various subtypes of differentiated trophoblast cells (DT cells) which includes trophoblast giant cells (TGC), spongiotrophoblast cells and labyrinthine trophoblasts. TS cell cultures can be established from blastocyst outgrowths, and withdrawal of specific growth factors results in the spontaneous differentiation into DT cells 3, 29 . Mouse TS cells (kindly provided by J. Cross, University of Calgary, Calgary, Canada) were maintained as previously described 3 . To obtain DT cells, TS cells were cultured without FGF4 and heparin for 96 hours. Jeg3 and BeWo human choriocarcinoma cell lines (ATCC, Manassas, VA) were maintained following the supplier's recommendations.
Microdissection of mouse placental tissues:
Trophoblasts and embryos were microdissected from E8.5 fetuses obtained from timed CD1 mouse matings at 8.5 days post coitum (dpc). The trophoblast shell containing the embryo was peeled from the surrounding decidual tissue, and subsequently separated from Reichert's 
Microarray hybridization and data analysis:
MGU74Av2 chips (Affymetrix, Santa Clara, CA) were used for all array experiments.
Probe synthesis, hybridizations, washing and scanning were performed according to Affymetrix protocols. Data was analyzed using MICROARRAY SUITE and DATA MINING TOOLS software (Affymetrix, Santa Clara, CA). "Present", "absent", "marginal" calls and "difference" calls were assigned by applying the DATA MINING TOOLS algorithm to data from 4 independent profiling experiments. Final score reflecting aggregate results from all 4 experiments was determined using the following criteria. Probe sets that scored "present" in at least two out of four expression profiles by the DATA MINING TOOLS algorithm were assigned a "present" call. The remaining probe sets that scored a signal of more than 60 (which equaled average background plus average noise in these experiments) in at least 2 out of 4 expression profiles were assigned a "marginal" call. All the rest were assigned an "absent" call. A gene was assigned "increased" in DT only if (i) it scored as "increased" in all four comparisons, and (ii) it scored "present" in DT cells. The average fold increase was calculated from all four comparisons.
Cluster analyses were carried out using GeneSpring 7.2 software (Silicon Genetics, Redwood city, CA). Standard correlation was used as the similarity measure for these analyses.
PCR analysis:
Total RNA was reverse-transcribed using superscript reverse transcriptase (Invitrogen Corporation, Carlsbad, CA) and PCR-amplified (primer sequences available upon request 
Calcium mobilization studies:
Intracellular Ca +2 measurements were performed as previously described 25 . Briefly, cells
were grown on cover slips, loaded with Fura-2-AM (Molecular Probes, Eugene, OR) and real time changes in the ratio of fluorescence levels upon excitation of clusters of 6 to 12 cells at 340
and 380 nm were measured in response to 10nM Thrombin or 100μM peptide agonists for Par1
(TFLLRNPND-NH2), Par2 (SLIGRL-NH2), Par4 (AYPGKF-NH2) and corresponding control peptides (FSLLRN-NH2, LSIGRL-NH2 and GAPGKF-NH2).
In situ hybridization:
In situ hybridizations were performed as previously described 13 
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Milano, Italy). TM cofactor activity was measured by a two-step assay for PC activation 27 .
Functional TFPI was determined by treating cells with phosphatidylinositol-specific phospholipase C [1 U/ml; 1 h, RT] to release cell-associated TFPI. TF-inhibitory activity in the cell-free supernatant was measured as previously described 28 .
Results:
Differentiation-dependent acquisition of an anticoagulant gene expression program by cultured trophoblast cells
The global gene expression profiles of TS and DT cells were analyzed using oligonucleotide arrays containing 12,488 probe sets corresponding to 9218 unigene entries. 6233
probe sets were expressed in TS or DT cells. Expression of ~19% (1177) TFPI mRNA was present in E8.5 and E9.5 TGC, overlapping with the expression of TF mRNA 13 . Parietal endoderm cells produced TF, but not TFPI mRNA (data not shown). At E12.5, TFPI expression was retained in the TGC population at the baso-lateral aspect of the placenta.
Protein C mRNA was detected in TGC at E8.5 and 9.5. At E9.5, expression extended to the labyrinth, and the parietal endoderm (not shown). At E12.5, placental expression of protein C was below the limit of detection. Protein S mRNA localized to the parietal endoderm, to patches of spongiotrophoblast cells and to maternal decidual cells in the mesometrial aspect of the decidua between E8.5 and 12.5. EPCR mRNA was present in TGC at E8.5 and 9.5, confirming published results obtained with EPCR-specific antibodies 7 . CD39 mRNA was present in, and restricted to, the TGC at E8.5 and E9.5. At E12.5 expression was observed in the labyrinth, the spongiotrophoblast layers, and in a subpopulation of TGC at the baso-lateral aspect of the placenta. Protease nexin-1 mRNA was expressed in a small group of cells at the mesometrial pole of the ectoplacental cone at E8. 
Functional activity of TF, TFPI and TM expressed by mouse trophoblast cells
The above analysis of mRNA expression suggested that both TS and DT cells constitutively produce the coagulation initiator, TF, whereas the expression of the coagulation 
Functional activity of protease activated receptors expressed by mouse trophoblasts
To assess the functional status of Pars expressed by trophoblast cells, we measured the ability of thrombin and receptor-specific agonist peptides to elicit changes in intracellular calcium levels in DT cells. Thrombin and agonist peptides for Par1, Par2 and Par4, but not sequencescrambled control peptides transiently increased intracellular calcium levels ( Figure 4A ). BeWo cells, we were unable to detect mRNA for protein C, protein S and 3-OST-1 in first trimester human placentae. EPCR was highly expressed in the cytotrophoblast-synctiotrophoblast bilayers of placental villi (figure 5), corresponding to expression seen in TGC and labyrinthine trophoblasts in mice, and overlapping the previously reported sites of high TM and TFPI expression 6, 8 . The distribution of CD39 mRNA was identical to that of EPCR mRNA. PN1
mRNA was localized on cytotrophoblast columns, analogous to its expression in mouse spongiotrophoblasts.
Discussion:
The goal of the current study was to delineate the role of trophoblast cells in placental This shows that, although derived from two distinct developmental lineages, endothelial cells and trophoblast cells activate a similar gene expression program that enables both cell types to partake in the regulation of hemostasis at the blood-tissue interface. In spite of it's cellular heterogeneity, the lining of the maternal blood space in the placenta is therefore homogeneous with respect to its thromboresistance. These observations extend the concept of "endothelial mimicry" by trophoblast cells beyond the subpopulation of endovascular trophoblast. In contrast to the temporally and spatially restricted phenotypic adaptation of endovascular trophoblast cells, the ability to regulate hemostasis in an endothelial cell-like fashion appears, at least in vitro, coupled to the spontaneous differentiation of trophoblast stem cells.
The group of thrombo-regulatory trophoblast gene products identified here represents a set of candidate genes that are potential modifiers of the risk for adverse pregnancy outcome experienced by mothers with a thrombophilic predisposition. Because trophoblast cells are of fetal origin, genetic polymorphisms of either parental genome have a 50% chance of germline transmission, and thereby affecting trophoblast function. In order to determine the true risk for adverse pregnancy outcome associated with these modifiers, it might be necessary to conduct a retrospective analysis of placental/fetal tissue, or -if viable-the offspring. Cell surface-associated membrane receptors and ectoenzymes, but not soluble factors, are likely the most relevant candidates, because they directly affect hemostasis at the feto-maternal interface. In contrast, polymorphisms in fetal genes encoding circulating factors will only affect hemostasis within the fetal blood vessel compartment, and therefore are unlikely to alter the risk conferred by maternal thrombophilia.
At present, direct proof for the critical role of trophoblast cells in the regulation of hemostasis at the feto-maternal interface derives exclusively from genetically modified mice:
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Animals lacking TM or EPCR expression on trophoblast cells succumb to fatal defects in placental development 13, [43] [44] [45] . 3-OST-1 knockout mice exhibit intrauterine growth restriction, but it is unknown whether this phenotype is caused by a trophoblast defect 46 . Similarly, TFPIdeficiency causes abnormalities including large maternal blood pools and increased fibrin deposition in the placenta 47, 48 . In all these animal models, the defects are solely due to the complete absence of these factors from fetal trophoblast, and are manifest in the absence of Placentae consisting of trophoblast shell were carefully peeled from the surrounding decidual tissue, and separated from Reichert's membrane, visceral yolk sac, and the embryo proper.
Dihydrofolate reductase (DHFR; house-keeping gene) and fibroblast growth factor 4 (FGF4; expressed only by the embryo) were included as controls. 
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